Table 1. Main characteristics of the... | American Society of Hematology

Table 1.

Main characteristics of the all-male patient population at entry of the study

Patient	Age (yr)	KS	Splenectomy	CD4⁺cells/mm³	HIV-RNA log copies/mL	Antiretroviral therapy	MCD therapy	Visits no.
1	42	No	No	217	4.39	Triple	VLB	1
2	51	Yes	No	126	< 2.3	Triple	VLB	15
3	34	No	No	56	6.08	No	VP16	12
4	38	No	No	490	4.01	No	VLB	2
5	46	No	No	194	3.62	Triple	No	1
6	34	Yes	No	110	4.16	No	VLB	4
7	54	Yes	Yes	362	4.51	Triple	VLB	2
8	37	Yes	No	292	< 2.3	Triple	VLB	3
9	35	Yes	No	329	4.56	No	VLB	3
10	49	Yes	Yes	603	< 2.3	Triple	VLB	1
11	55	Yes	No	174	3.66	Triple	VLB	3
12	48	Yes	No	252	< 2.3	Triple	No	1
13	34	Yes	No	258	4.89	Triple	VLB	10
14	47	No	No	68	4.88	Triple	VP16	1
15	45	Yes	Yes	360	< 2.3	Triple	VLB	9
16	35	No	No	373	5.41	Double	VLB	5
17	53	No	No	110	5.56	No	No	1
18	40	Yes	Yes	241	2.6	Triple	VP16	1
19	48	Yes	No	280	< 2.3	Triple	VLB	6
20	57	Yes	Yes	1086	< 2.3	Triple	VP16	2
21	52	No	No	205	< 2.3	Triple	No	4
22	69	Yes	Yes	512	< 2.3	Triple	VLB	1
23	32	No	Yes	334	4.57	Triple	VLB	7

Patient	Age (yr)	KS	Splenectomy	CD4⁺cells/mm³	HIV-RNA log copies/mL	Antiretroviral therapy	MCD therapy	Visits no.
1	42	No	No	217	4.39	Triple	VLB	1
2	51	Yes	No	126	< 2.3	Triple	VLB	15
3	34	No	No	56	6.08	No	VP16	12
4	38	No	No	490	4.01	No	VLB	2
5	46	No	No	194	3.62	Triple	No	1
6	34	Yes	No	110	4.16	No	VLB	4
7	54	Yes	Yes	362	4.51	Triple	VLB	2
8	37	Yes	No	292	< 2.3	Triple	VLB	3
9	35	Yes	No	329	4.56	No	VLB	3
10	49	Yes	Yes	603	< 2.3	Triple	VLB	1
11	55	Yes	No	174	3.66	Triple	VLB	3
12	48	Yes	No	252	< 2.3	Triple	No	1
13	34	Yes	No	258	4.89	Triple	VLB	10
14	47	No	No	68	4.88	Triple	VP16	1
15	45	Yes	Yes	360	< 2.3	Triple	VLB	9
16	35	No	No	373	5.41	Double	VLB	5
17	53	No	No	110	5.56	No	No	1
18	40	Yes	Yes	241	2.6	Triple	VP16	1
19	48	Yes	No	280	< 2.3	Triple	VLB	6
20	57	Yes	Yes	1086	< 2.3	Triple	VP16	2
21	52	No	No	205	< 2.3	Triple	No	4
22	69	Yes	Yes	512	< 2.3	Triple	VLB	1
23	32	No	Yes	334	4.57	Triple	VLB	7

KS indicates Kaposi sarcoma; HIV, human immunodeficiency virus; MDC, multicentric Castleman disease; VLB, vinblastine; VP16, etoposide.